Meningioma other diagnostic studies: Difference between revisions
Jump to navigation
Jump to search
Sergekorjian (talk | contribs) |
Mahshid |
||
| Line 21: | Line 21: | ||
[[Category:Neurosurgery]] | [[Category:Neurosurgery]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Neurology]] | |||
[[Category:Neurosurgery]] | |||
Revision as of 02:38, 27 November 2017
|
Meningioma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Meningioma other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Meningioma other diagnostic studies |
|
Risk calculators and risk factors for Meningioma other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Haytham Allaham, M.D. [2]
Overview
Bromodeoxyuridine labeling study may be helpful in the diagnosis of meningioma. An elevated bromodeoxyuridine labeling index is suggestive of a rapid growth rate of meningioma and a greater incidence of recurrence following surgical resection.[1]
Other Diagnostic Studies
Bromodeoxyuridine Labeling Study
- An elevated bromodeoxyuridine labeling index of meningioma is associated with:[1]
- Rapid growth rate of the tumor
- Greater incidence of recurrence following surgical resection of the tumor
References
- ↑ 1.0 1.1 Lee KS, Hoshino T, Rodriguez LA, Bederson J, Davis RL, Wilson CB (1990). "Bromodeoxyuridine labeling study of intracranial meningiomas: proliferative potential and recurrence". Acta Neuropathol. 80 (3): 311–7. PMID 2399811.